At the point in time the trials were put together s2c was
At the point in time the trials were put together s2c was much more of a death sentence than it was now however. This is when NYC was overrun with patients and they were triaging due to lack of equipment. I understand your argument that we didn't have 40 EIND patients to support our request but given the safety profile and the fact that we had given 4 doses to some if not all of the Montefiore patients, why would you, a regulatory authority, effectively ask for an m2m dosing regiment that was identical to the s2c regiment? That makes no sense to me and it obviously made no sense to Dr. Jay.
The only rationale I have is that the FDA still did not believe our MOA or the theory put forth by Dr. Patterson and therefore was erring on the side of being cautious? I dunno. Scratch that. It makes no sense to me still. Assuming what Dr. Jay said was true (and I have no reason to doubt him) then I cannot rationalize pushing us to have the same dosing between the two trials when we requested additional dosing for s2c. Given our safety profile, the half life of the drug and our MOA I am at a loss. I would be happy to hear their reasoning. If they didn't want to allow it because they wanted more patient data first, what were they hoping to understand that they didn't previously? That the "cytokine storm" was more severe in s2c than m2m???
Add it to the CYDY shareholder mystery bucket along with the additional requirements to get approval for HIV combo vis-a-vis mono, vis-a-vis RO tests. One day, all will be revealed, or not. More likely not. : -)
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Top 5 Most Recently Viewed Articles
Innovative Partnership for Autonomous Steel Transportation Nippon Steel Corporation, known as Japan's largest steel manufacturer, has initiated a significant collaboration with TIER IV, Inc., a trailblazer in the development of open-source software for autonomous driving. This partnership is set to revolutionize the way steel is transported within manufacturing...
Continue Reading
The Brock Group Expands Leadership with New Regional Units The Brock Group is taking significant strides in enhancing its Brock Industrial Services (BIS) division. Recently, the company announced the creation of two new regional operating units designed to bolster its service capabilities and responsiveness for customers nationwide. Under this new organizational...
Continue Reading
Rising Interest in Nasdaq-100 Index for Retirement Investments Recent findings reveal a burgeoning interest in the Nasdaq-100 Index among retirement plan participants. This trend signifies a noteworthy opportunity for retirement investment options catering to the needs of a modern workforce. A recent survey indicated that nearly 80 percent of 401(k) plan participants...
Continue Reading
Important Updates Regarding ModivCare Lawsuit Levi & Korsinsky, LLP is reaching out to investors who have been part of ModivCare Inc. (NASDAQ: MODV) regarding a pivotal class action securities lawsuit. This notification signals a chance for investors affected by the Company’s alleged securities fraud to seek compensation. Understanding the Class Action Lawsuit The...
Continue Reading
Essential Details for the Upcoming Annual General Meeting The Annual General Meeting (AGM) of Nordic Fibreboard AS (registry code: 11421437) will be convened to discuss pivotal matters affecting the company's future. Set to take place at the headquarters in Pärnu, Estonia, the AGM is a prime opportunity for shareholders to engage directly with the company's management...
Continue Reading